Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis

Moses Rodriguez, Kevin D. Pavelko, Christopher W. McKinney, Julian L. Leibowitz

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

We used a murine model of multiple sclerosis (MS) induced by Theiler's murine encephalomyelitis virus (TMEV) to test the effect of IL-6 on central nervous system (CNS) demyelination. Administration of human rIL-6 (2.5 μg/dose), beginning one day before infection and then twice daily for 28 days, dramatically reduced demyelination and inflammation in the spinal cord of susceptible SJL/J mice. Benefit also was observed when rIL-6 was used as a therapeutic agent and begun on day 15 after infection, a time in which there is the first evidence of inflammation and demyelination in the spinal cord. Suppression of myelin damage by treatment with rIL-6 was associated with fewer virus Ag-positive cells in the spinal cord. Infectious CNS virus titers, as measured by plaque assay, were reduced in rIL-6-treated animals on day 15 after infection, but not on day 7, 22, or 29 after infection. Total serum Igs and virus-specific Igs, as detected by indirect ELISA, were increased markedly in rIL-6-treated mice, whereas no effect was observed on TMEV-neutralizing Ab titers. In vivo administration of rIL-6 inhibited a murine CNS-demyelinating disease induced by a virus, suggesting that this IL may have application for the treatment of human MS.

Original languageEnglish (US)
Pages (from-to)3811-3821
Number of pages11
JournalJournal of Immunology
Volume153
Issue number8
StatePublished - Oct 15 1994

Fingerprint

Demyelinating Diseases
Multiple Sclerosis
Interleukin-6
Theilovirus
Viruses
Infection
Spinal Cord
Central Nervous System
Myelitis
Central Nervous System Diseases
Myelin Sheath
Viral Load
Therapeutics
Enzyme-Linked Immunosorbent Assay
Inflammation
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Rodriguez, M., Pavelko, K. D., McKinney, C. W., & Leibowitz, J. L. (1994). Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. Journal of Immunology, 153(8), 3811-3821.

Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. / Rodriguez, Moses; Pavelko, Kevin D.; McKinney, Christopher W.; Leibowitz, Julian L.

In: Journal of Immunology, Vol. 153, No. 8, 15.10.1994, p. 3811-3821.

Research output: Contribution to journalArticle

Rodriguez, M, Pavelko, KD, McKinney, CW & Leibowitz, JL 1994, 'Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis', Journal of Immunology, vol. 153, no. 8, pp. 3811-3821.
Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. Journal of Immunology. 1994 Oct 15;153(8):3811-3821.
Rodriguez, Moses ; Pavelko, Kevin D. ; McKinney, Christopher W. ; Leibowitz, Julian L. / Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. In: Journal of Immunology. 1994 ; Vol. 153, No. 8. pp. 3811-3821.
@article{487079e1ea1e4b8ca201063066c67d95,
title = "Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis",
abstract = "We used a murine model of multiple sclerosis (MS) induced by Theiler's murine encephalomyelitis virus (TMEV) to test the effect of IL-6 on central nervous system (CNS) demyelination. Administration of human rIL-6 (2.5 μg/dose), beginning one day before infection and then twice daily for 28 days, dramatically reduced demyelination and inflammation in the spinal cord of susceptible SJL/J mice. Benefit also was observed when rIL-6 was used as a therapeutic agent and begun on day 15 after infection, a time in which there is the first evidence of inflammation and demyelination in the spinal cord. Suppression of myelin damage by treatment with rIL-6 was associated with fewer virus Ag-positive cells in the spinal cord. Infectious CNS virus titers, as measured by plaque assay, were reduced in rIL-6-treated animals on day 15 after infection, but not on day 7, 22, or 29 after infection. Total serum Igs and virus-specific Igs, as detected by indirect ELISA, were increased markedly in rIL-6-treated mice, whereas no effect was observed on TMEV-neutralizing Ab titers. In vivo administration of rIL-6 inhibited a murine CNS-demyelinating disease induced by a virus, suggesting that this IL may have application for the treatment of human MS.",
author = "Moses Rodriguez and Pavelko, {Kevin D.} and McKinney, {Christopher W.} and Leibowitz, {Julian L.}",
year = "1994",
month = "10",
day = "15",
language = "English (US)",
volume = "153",
pages = "3811--3821",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis

AU - Rodriguez, Moses

AU - Pavelko, Kevin D.

AU - McKinney, Christopher W.

AU - Leibowitz, Julian L.

PY - 1994/10/15

Y1 - 1994/10/15

N2 - We used a murine model of multiple sclerosis (MS) induced by Theiler's murine encephalomyelitis virus (TMEV) to test the effect of IL-6 on central nervous system (CNS) demyelination. Administration of human rIL-6 (2.5 μg/dose), beginning one day before infection and then twice daily for 28 days, dramatically reduced demyelination and inflammation in the spinal cord of susceptible SJL/J mice. Benefit also was observed when rIL-6 was used as a therapeutic agent and begun on day 15 after infection, a time in which there is the first evidence of inflammation and demyelination in the spinal cord. Suppression of myelin damage by treatment with rIL-6 was associated with fewer virus Ag-positive cells in the spinal cord. Infectious CNS virus titers, as measured by plaque assay, were reduced in rIL-6-treated animals on day 15 after infection, but not on day 7, 22, or 29 after infection. Total serum Igs and virus-specific Igs, as detected by indirect ELISA, were increased markedly in rIL-6-treated mice, whereas no effect was observed on TMEV-neutralizing Ab titers. In vivo administration of rIL-6 inhibited a murine CNS-demyelinating disease induced by a virus, suggesting that this IL may have application for the treatment of human MS.

AB - We used a murine model of multiple sclerosis (MS) induced by Theiler's murine encephalomyelitis virus (TMEV) to test the effect of IL-6 on central nervous system (CNS) demyelination. Administration of human rIL-6 (2.5 μg/dose), beginning one day before infection and then twice daily for 28 days, dramatically reduced demyelination and inflammation in the spinal cord of susceptible SJL/J mice. Benefit also was observed when rIL-6 was used as a therapeutic agent and begun on day 15 after infection, a time in which there is the first evidence of inflammation and demyelination in the spinal cord. Suppression of myelin damage by treatment with rIL-6 was associated with fewer virus Ag-positive cells in the spinal cord. Infectious CNS virus titers, as measured by plaque assay, were reduced in rIL-6-treated animals on day 15 after infection, but not on day 7, 22, or 29 after infection. Total serum Igs and virus-specific Igs, as detected by indirect ELISA, were increased markedly in rIL-6-treated mice, whereas no effect was observed on TMEV-neutralizing Ab titers. In vivo administration of rIL-6 inhibited a murine CNS-demyelinating disease induced by a virus, suggesting that this IL may have application for the treatment of human MS.

UR - http://www.scopus.com/inward/record.url?scp=0027939355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027939355&partnerID=8YFLogxK

M3 - Article

C2 - 7930598

AN - SCOPUS:0027939355

VL - 153

SP - 3811

EP - 3821

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -